Mouse models of nonalcoholic steatohepatitis in preclinical drug development
- PMID: 28687459
- DOI: 10.1016/j.drudis.2017.06.007
Mouse models of nonalcoholic steatohepatitis in preclinical drug development
Abstract
Nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease in the Western world. NAFLD is a complex spectrum of liver diseases ranging from benign hepatic steatosis to its more aggressive necroinflammatory manifestation, nonalcoholic steatohepatitis (NASH). NASH pathogenesis is multifactorial and risk factors are almost identical to those of the metabolic syndrome. This has prompted substantial efforts to identify novel drug therapies for correcting underlying metabolic deficits, and to prevent or alleviate hepatic fibrosis in NASH. Available mouse models of NASH address different aspects of the disease, have varying clinical translatability, and, therefore, also show different utility in drug discovery.
Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
Non-alcoholic fatty liver disease (NAFLD) models in drug discovery.Expert Opin Drug Discov. 2018 Feb;13(2):193-205. doi: 10.1080/17460441.2018.1410135. Epub 2017 Dec 6. Expert Opin Drug Discov. 2018. PMID: 29190166 Review.
-
How effective are nonalcoholic fatty liver disease models for drug discovery?Expert Opin Drug Discov. 2020 Nov;15(11):1237-1240. doi: 10.1080/17460441.2020.1776258. Epub 2020 Jun 11. Expert Opin Drug Discov. 2020. PMID: 32524859
-
Promising therapies for treatment of nonalcoholic steatohepatitis.Expert Opin Emerg Drugs. 2016 Sep;21(3):343-57. doi: 10.1080/14728214.2016.1220533. Epub 2016 Aug 28. Expert Opin Emerg Drugs. 2016. PMID: 27501374 Free PMC article. Review.
-
Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research.Digestion. 2019;100(2):79-85. doi: 10.1159/000493259. Epub 2018 Dec 7. Digestion. 2019. PMID: 30537758 Review.
-
Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research.Int J Mol Sci. 2020 Dec 17;21(24):9646. doi: 10.3390/ijms21249646. Int J Mol Sci. 2020. PMID: 33348908 Free PMC article. Review.
Cited by
-
Kupffer cells dictate hepatic responses to the atherogenic dyslipidemic insult.Nat Cardiovasc Res. 2024 Mar;3(3):356-371. doi: 10.1038/s44161-024-00448-6. Epub 2024 Mar 11. Nat Cardiovasc Res. 2024. PMID: 39196121 Free PMC article.
-
Role of the type 3 cytokines IL-17 and IL-22 in modulating metabolic dysfunction-associated steatotic liver disease.Front Immunol. 2024 Aug 2;15:1437046. doi: 10.3389/fimmu.2024.1437046. eCollection 2024. Front Immunol. 2024. PMID: 39156888 Free PMC article. Review.
-
Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH.BMC Gastroenterol. 2019 Dec 28;19(1):228. doi: 10.1186/s12876-019-1149-z. BMC Gastroenterol. 2019. PMID: 31883514 Free PMC article.
-
Exercise Intervention Mitigates Pathological Liver Changes in NAFLD Zebrafish by Activating SIRT1/AMPK/NRF2 Signaling.Int J Mol Sci. 2021 Oct 10;22(20):10940. doi: 10.3390/ijms222010940. Int J Mol Sci. 2021. PMID: 34681600 Free PMC article.
-
Nonalcoholic steatohepatitis severity is defined by a failure in compensatory antioxidant capacity in the setting of mitochondrial dysfunction.World J Gastroenterol. 2018 Apr 28;24(16):1748-1765. doi: 10.3748/wjg.v24.i16.1748. World J Gastroenterol. 2018. PMID: 29713129 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical